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ACR Appropriateness Criteria® on
Cerebrovascular Disease
Robert L. DeLaPaz, MDa, Franz J. Wippold II, MDb, Rebecca S. Cornelius, MDc,
Sepideh Amin-Hanjani, MDd,e,f, Edgardo J. Angtuaco, MDg,
Daniel F. Broderick, MDh, Douglas C. Brown, MDi, Jeffrey L. Creasy, MDj,
Patricia C. Davis, MDk, Charles F. Garvin, MDl, Brian L. Hoh, MDe,f,m,
Charles T. McConnell Jr, MDn, Laszlo L. Mechtler, MDo,p,
David J. Seidenwurm, MDq, James G. Smirniotopoulos, MDr, Paul J. Tobben, MDs,
Alan D. Waxman, MDt,u, and Greg J. Zipfel, MDe,f,v
Stroke is the sudden onset of focal neurologic symptoms due to ischemia or hemorrhage in the brain. Current
FDA-approved clinical treatment of acute ischemic stroke involves the use of the intravenous thrombolytic agent
recombinant tissue plasminogen activator given ⬍3 hours after symptom onset, following the exclusion of intracerebral hemorrhage by a noncontrast CT scan. Advanced MRI, CT, and other techniques may confirm the stroke
diagnosis and subtype, demonstrate lesion location, identify vascular occlusion, and guide other management
decisions but, within the first 3 hours after ictus, should not delay or be used to withhold recombinant tissue
plasminogen activator therapy after the exclusion of acute hemorrhage on noncontrast CT scans. MR diffusionweighted imaging is highly sensitive and specific for acute cerebral ischemia and, when combined with perfusionweighted imaging, may be used to identify potentially salvageable ischemic tissue, especially in the period ⬎3 hours
after symptom onset. Advanced CT perfusion methods improve sensitivity to acute ischemia and are increasingly
used with CT angiography to evaluate acute stroke as a supplement to noncontrast CT. The ACR Appropriateness
Criteria® are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical
literature from peer-reviewed journals and the application of a well-established consensus methodology (modified
Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances in which
evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
Key Words: Appropriateness Criteria®, stroke, transient ischemic attack, TIA, thrombolysis, hemorrhage,
aneurysm
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SUMMARY OF LITERATURE REVIEW
Introduction/Background

Diseases of the cerebral vasculature are often manifested
as stroke, a generic term encompassing a range of ischemic and hemorrhagic lesions. There are approximately
795,000 new (610,000) or recurrent (185,000) strokes
per year in the United States, an average of 1 every 40
seconds [1]. Stroke is the third leading underlying or
contributing cause of death in the United States, behind
heart disease and cancer, accounting for 1 in every 18
(137,265) deaths in 2006, an average of 1 death every 3
to 4 minutes [1]. Of all strokes, 87% are ischemic, 10%
are intracerebral hemorrhages, and 3% are subarachnoid
hemorrhages [1]. Significant functional disability is common in nonfatal cases, and stroke is a leading cause of
serious, long-term disability in the United States [1]. The
estimated direct and indirect cost of stroke in the United
States in 2009 was $68.9 billion [1].
Imaging and Stroke Risk

Because of the gravity of stroke’s sequelae, considerable effort has been expended to identify risk factors
for the disease and strategies for stroke prevention in
high-risk patients [2]. Although the diagnostic accuracies of duplex ultrasound, CT angiography (CTA),
MR angiography (MRA) and time-resolved contrastenhanced MRA are all high for internal carotid artery
stenosis (70% to 99%) [3,4], only ultrasound seems to
offer cost-effective initial screening. Combined use of
ultrasound and contrast-enhanced MRA is an increasingly common practice [5-9].
Multislice CTA is promising, but relatively few rigorous studies have been done, and the technique remains
limited by the large intravenous (IV) contrast injection
volumes required, the potential contrast toxicity or reaction, the radiation dose, and the plaque calcification that
may obscure the stenosis [4,10,11]. The predictive value
of carotid stenosis for symptomatic cerebral ischemia
may be further improved by direct characterization of the
atherosclerotic plaque [12,13].
Elevated ischemic stroke risk in patients with chronic
carotid stenosis or occlusion can also be identified by
using single photon-emission CT and research xenon CT
methods, which show reduced cerebral vascular reserve
after acetazolamide challenge, or by elevated oxygen extraction fraction using 15O PET [14-16]. Although there
is limited experience with MR and CT perfusion methods for this purpose, elevated cerebral blood volume
seems to correlate with reduced cerebral vascular reserve
and increased stroke risk [17,18], and these modalities
are more widely available than PET.

tion can be classified into various subgroups on the
basis of the mechanism of the ischemia (hemodynamic
or thromboembolic) and the pathology of the vascular
lesion: atherosclerotic, lacunar, cardioembolic, or indeterminate.
Thrombolytic Treatment

Current clinical practice in the United States is based
on the 1996 FDA approval of the thrombolytic agent
recombinant tissue plasminogen activator (rtPA)
given intravenously, preferably ⬍1 hour and no later
than 3 hours after symptom onset, after the exclusion
of intracerebral hemorrhage by a noncontrast CT
(NCCT) scan [19]. The Joint Commission has included these criteria in its requirements for stroke
center designation [20]. Recommendations also include the performance of NCCT within 25 minutes of
admission and expert interpretation within 20 minutes (45-minute “door-to-interpretation” time) [21].
Recent increases in public awareness, emergency medical response, and the establishment of dedicated
stroke centers have resulted in 19% to 60% of admissions arriving at treatment centers ⬍3 hours after
symptom onset. However, after appropriate medical
exclusions, successful treatment with rtPA, without
symptomatic major hemorrhage, is limited to 3% to
8.5% of ischemic stroke admissions [21-24].
Transient Ischemic Attack

Traditionally, if focal neurologic symptoms continued
for ⬎24 hours, stroke was diagnosed; otherwise, a focal
neurologic deficit lasting ⬍24 hours was defined as a
transient ischemic attack (TIA). However, this timebased definition of TIA may be inadequate and misleading, potentially leading to inappropriate delays in diagnosis and treatment. A “tissue-based” definition has been
proposed that considers all acute focal neurologic deficits
as possible infarcts and classifies them as “acute neurovascular syndromes” or “acute ischemic cerebrovascular
syndromes” on the basis of the degree of certainty of
tissue ischemic injury, which is determined primarily by
tissue and vascular imaging studies [25-27]. Because
most transient ischemic neurologic symptoms (70%) last
for ⱕ2 hours and 30% to 50% show tissue injury on MR
diffusion-weighted imaging (DWI) [26,28,29], the
American Stroke Association recently proposed a new
definition of TIA as “a transient episode of neurological
dysfunction caused by focal brain, spinal cord, or retinal
ischemia, without acute infarction” [25,28]. This change
reflects the growing emphasis on the earliest possible
diagnosis and treatment of acute ischemia and the use of
NCCT for exclusion of hemorrhage and MRI for definitive infarct diagnosis [21,28].

Clinical Characteristics of Stroke

Clinically, stroke is most often characterized by the
ictal onset of focal neurologic symptoms due to ischemia or hemorrhage into the brain. Ischemic infarc-

MRI

Rapid and accurate diagnosis of ischemia, completed infarction, and hemorrhage has become paramount in im-
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portance for treating acute cerebrovascular disease because of the demonstrable benefit (and hemorrhage risk)
of acute IV and intra-arterial thrombolytic therapy for
cerebral ischemia in prospective clinical trials [22-24,3037]. MRI in the form of DWI has been shown to be
exquisitely sensitive to acute infarction within minutes
of the precipitating ictus, with sensitivity of 88% to
100% compared to NCCT’s mean sensitivity of 66%
(range, 20%-87%) [38-41]. The specificity of DWI
for ischemic injury is also high (95%-100%), although
small reductions in apparent diffusion coefficient (eg,
20% below normal) can represent reversible ischemia
that may not progress to completed infarct [42]. Additional information obtainable through the combined use of dynamic cerebral blood volume techniques (perfusion-weighted imaging [PWI] as well as
vascular imaging [MRA]) makes MRI an appealing
tool for diagnosis and treatment monitoring of acute
cerebrovascular disease [41-45].
However, enthusiasm for MRI in the setting of acute
stroke has been tempered by the variable and confounding appearance of hemorrhage. Recent experience using
T2* (gradient-echo) imaging to detect low-signal parenchymal hemorrhage and fluid-attenuated inversion recovery scans to detect high-signal subarachnoid blood
(subarachnoid hemorrhage) have helped renew interest
in MRI as a first-line modality in patients with acute,
focal neurologic deficits [46-48]. However, there is currently insufficiently widespread clinical experience to recommend MRI over CT for routine exclusion of parenchymal hemorrhage or to withhold rtPA therapy in the
presence of microhemorrhages on MRI within the first 3
hours after ictus [21,47].
Because of the small percentage of patients with acute
stroke treated within the 3-hour limit, there is growing
interest in expanding the treatment window without increasing hemorrhage risk. A pooled risk-benefit analysis
of existing rtPA trials using NCCT scan exclusion of
hemorrhage has suggested that treatment may be safe in
some patients out to 4.5 hours after ictus [22,32], but
FDA and American Stroke Association recommendations have not yet been modified to include this expanded treatment window in published guidelines. In
addition, several current clinical trials are focused on the
use of thrombolytic and neuroprotective agents combined with MRI techniques to expand the treatment
window by identifying the “ischemic penumbra,” the
underperfused yet viable halo of brain parenchyma
around or interspersed with the region of completed infarction that is at risk for progressing to infarction. Gadolinium bolus dynamic susceptibility contrast MR PWI
measures tissue blood flow parameters (cerebral blood
flow, cerebral blood volume, mean transit time, and time
to peak) on the basis of the central volume principle and
is being used to identify the volume of tissue with reduced blood flow, which is then compared with the vol-

ume of presumed infarcted tissue as indicated by restricted diffusion (reduced apparent diffusion coefficient
on DWI). When the low-blood flow tissue volume is
larger than the restricted diffusion volume by ⱖ20%, a
perfusion-diffusion (PWI-DWI) “mismatch” is said to
exist as an indicator of potentially salvageable tissue. Imaging of oxygen metabolism may further define potentially salvageable tissue within this mismatch zone by
demonstrating regions of elevated oxygen extraction fraction in stage II “misery perfusion,” including DWI-positive (restricted diffusion) regions [14,49,50]. Images of
oxygen metabolism can be acquired using 15O PET or
experimental MRI methods, and images of hypoxemic
tissue can be obtained with 18F fluoromisonidazole PET,
but these imaging techniques are not currently available
in general clinical practice [50-52]. Currently, there is
insufficient scientific evidence or widespread clinical experience to recommend these diagnostic approaches for
routine thrombolytic treatment beyond the 3-hour window after symptom onset [53].
CT

On the basis of ready availability and high sensitivity
to the presence or absence of acute blood, NCCT
historically has been the preferred modality for initial
imaging of suspected stroke but has lacked a similar
sensitivity to acute ischemia and infarction. The relatively low sensitivity of NCCT to early ischemic injury
(only one-third to two-thirds of lesions detected in
various studies) and the variable quantitation and interpretation of ischemic changes have limited their use
in early stroke management.
A recent resurgence in the use of CT for initial stroke
evaluation has occurred with the increasing clinical availability of CT perfusion and CTA. CT perfusion is acquired by rapid scanning during a bolus IV contrast
infusion, and blood flow parameters (cerebral blood
flow, cerebral blood volume, mean transit time, and time
to peak) are calculated on the basis of the central volume
principle. This has transformed CT into a technique
with high sensitivity to cerebrovascular abnormalities
and early perfusion deficits, detectable before observable
low-density changes on NCCT [39,54]. Quantitative
CT perfusion measurements of cerebral blood flow parameters have been proposed as a means of discriminating between infarct and penumbra and have been compared favorably with MRI [55-61]. These measurements,
plus the ability to quickly identify acute hemorrhage and
vascular occlusive lesions as well as the ubiquitous availability of CT scanners, have been suggested as the key
advantages of CT over MRI for acute stroke evaluation.
However, greater risks of renal toxicity, contrast reaction,
or fluid overload from iodinated contrast materials vs
gadolinium, the variability in CT perfusion quantitative
methods [61], and the lack of a direct measure of cellular
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viability such as diffusion restriction mitigate these advantages over MRI [62].

app_criteria/pdf/ExpertPanelonNeurologicImaging/
CerebrovascularDiseaseDoc2.aspx (see Variant 1).

Acute Stroke and Advanced Imaging

Assumptions

It should be emphasized that the current FDA-approved treatment for acute ischemic stroke symptoms
is IV rtPA within 3 hours of symptom onset and that
the recommended imaging study is NCCT to exclude
acute hemorrhage. The multimodality MRI and CT
studies described above may be useful to confirm the
stroke diagnosis and subtype, demonstrate lesion location, identify vascular occlusion, and guide other
management decisions within and beyond the 3-hour
period. But the American Stroke Association guidelines and others specifically recommend that emergency IV rtPA treatment within the first 3 hours after
ictus not be delayed in order to obtain multimodality
imaging studies and that treatment not be withheld on
the basis of either positive or negative MRI or CT
findings, other than acute hemorrhage on NCCT
[47,53,60,63-65].
A more complete literature review is available at http://
www.acr.org/SecondaryMainMenuCategories/quality_safety/

All patient scenarios should be addressed as though the
patient had been referred for imaging after a history and
physical examination that include neurologic, vascular,
and ophthalmoscopic examinations.
ANTICIPATED EXCEPTIONS

Nephrogenic systemic fibrosis is a disorder with a scleroderma-like presentation and a spectrum of manifestations that can range from limited clinical sequelae to
fatality. It seems to be related to both underlying severe
renal dysfunction and the administration of gadoliniumbased contrast agents. It has occurred primarily in patients on dialysis, rarely in patients with very limited
glomerular filtration rates (ie, ⬍30 mL/min/1.73 m2),
and almost never in other patients. There is growing
literature regarding nephrogenic systemic fibrosis. Although some controversy and lack of clarity remain,
there is a consensus that it is advisable to avoid all gadolinium-based contrast agents in dialysis-dependent patients unless the possible benefits clearly outweigh the

Variant 1. New focal neurologic defect, fixed or worsening; ⬍3 hours
Radiologic Procedure
Rating
Comments
CT head without contrast

9

MRI head with or without contrast

8

MRA head and neck with or without
contrast
CT head with contrast

8

CTA head and neck with contrast

8

CT perfusion head

6

Arteriography neck
Arteriography cervicocerebral
Ultrasound carotid with Doppler
Ultrasound transcranial with Doppler
MRI functional head
MRI spectroscopy head
15
O PET head
99m
Tc HMPAO SPECT head

5
5
2
2
1
1
1
1

8

Noncontrast head CT, to exclude acute intracranial hemorrhage, is
needed prior to rtPA thrombolytic therapy. Delaying or
withholding rtPA thrombolysis in the 3-hour window after
symptom onset on the basis of multimodality MRI (DWI, PWI,
GRE, or MRA) or CT (CTP or CTA) may not be medically
appropriate.ⴱ
Consider DSC PWI if stenosis found. MRI with DWI preferred if
thrombolytic treatment not delayed or withheld.†
Combined vascular and cerebral evaluation should be
considered.†
Combined vascular and cerebral evaluation should be
considered.ⴱ
Combined vascular and cerebral evaluation should be
considered.ⴱ
In this scenario, CTP and CTA are equally useful and can be
obtained together (with two injections on most scanners or one
injection on volume CT) (but should not delay rtPA therapy
decision).ⴱ
If intra-arterial therapy is considered.
If intra-arterial therapy is considered.

RRL

⌷
⌷

⌷
⌷
⌷
⌷

Note: Rating scale: 1, 2, and 3 ⫽ usually not appropriate; 4, 5, and 6 ⫽ may be appropriate; 7, 8, and 9 ⫽ usually appropriate. Variant tables addressing
10 additional cerebrovascular disease scenarios are available at http://www.acr.org/SecondaryMainMenuCategories/quality_safety/app_criteria/pdf/
ExpertPanelonNeurologicImaging/CerebrovascularDiseaseDoc2.aspx. CTA ⫽ CT angiography; CTP ⫽ CT perfusion; DSC ⫽ dynamic susceptibility
contrast; DWI ⫽ diffusion-weighted imaging; GRE ⫽ gradient echo; HMPAO ⫽ hexamethylpropyleneamine oxime; MRA ⫽ MR angiography; PWI ⫽
perfusion-weighted imaging; RRL ⫽ relative radiation level; rtPA ⫽ recombinant tissue plasminogen activator; SPECT ⫽ single photon-emission CT.

ⴱSee text under “Relative Radiation Level Information” for important radiation dose warnings with multiple or repeated CT procedures.
†See statement regarding contrast in text under “Anticipated Exceptions.”
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Table 1. Relative radiation level designations
Pediatric Effective
Adult Effective
Relative
Dose Estimate
Dose Estimate
Radiation
Range (mSv)
Range (mSv)
Level
⌷

0
⬍0.1
0.1-1
1-10
10-30
30-100

0
⬍0.03
0.03-0.3
0.3-3
3-10
10-30

Note: Relative radiation level assignments for some of the examinations
cannot be made, because the actual patient doses in these procedures
vary as a function of a number of factors (eg, region of the body exposed
to ionizing radiation, the imaging guidance that is used). The relative
radiation levels for these examinations are designated as not specified.

risk and to limit the type and amount in patients with
estimated glomerular filtration rates ⬍ 30 mL/min/1.73
m2. For more information, please see the ACR’s Manual
on Contrast Media [66].
RELATIVE RADIATION LEVEL INFORMATION

CT stroke protocols combining brain NCCT, CTA, and
CT perfusion may produce a relative radiation level
, and repeated use of this protocol in an
(RRL) of
individual patient may result in high radiation exposure
) to the scalp and eyes.
(eg, RRL of
Potential adverse health effects associated with radiation exposure are an important factor to consider when
selecting the appropriate imaging procedure. Because
there is a wide range of radiation exposures associated
with different diagnostic procedures, an RRL indication
has been included for each imaging examination. The
RRLs are based on effective dose, which is a radiation
dose quantity that is used to estimate population total
radiation risk associated with an imaging procedure. Patients in the pediatric age group are at inherently higher
risk from exposure, both because of organ sensitivity and
longer life expectancy (relevant to the long latency that
appears to accompany radiation exposure). For these reasons, the RRL dose estimate ranges for pediatric examinations are lower compared with those specified for
adults (Table 1). Additional information regarding radiation dose assessment for imaging examinations can be
found in ACR Appropriateness Criteria®: Radiation Dose
Assessment Introduction [67].
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